Significance of serum hepcidin in assessment of liver inflammation activity among patients with chronic hepatitis B
HU Yinfei1,2, HE Tao2, FEI Yunxia2, ZHANG Xiangbo2, WANG Jie2, GONG Ling2, PAN Xiaoben2,3, CHEN Gongying2,3
1. The Fourth Clinical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China; 2. Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang 310015, China; 3. Hangzhou Normal University, Hangzhou, Zhejiang 311121, China
Abstract：Objective To investigate the value of serum hepcidin in assessment of liver inflammation activity among patients with chronic hepatitis B ( CHB ), so as to provide insights into the assessment of liver inflammation activity among CHB patients. Methods A total of 79 CHB patients who were admitted to the Affiliated Hospital of Hangzhou Normal University were selected as the experimental group, while 40 healthy volunteers were randomly sampled as controls. Subjects'demographic data, liver function tests and iron metabolism parameters were collected from medical records, and serum hepcidin was measured using enzyme-linked immunosorbent assay ( ELISA ). In addition, ultrasound-guided liver biopsy was performed in CHB patients, and mild and moderate-to-severe CHB were classified according to liver inflammation activity and degree of liver fibrosis. Serum hepcidin levels were compared between the experimental and control groups and between patients with mild and moderate-to-severe CHB. The value of serum hepcidin in assessment of liver inflammation activity was examined among CHB patients using the receiver operating characteristic ( ROC ) curve analysis. Results Subjects in the experimental group included 54 men ( 68.35% ) and had a mean age of ( 39.06±10.67 ) years, while the controls included 24 men (60.00%) and had a mean age of ( 42.43±11.44 ) years. Lower hepcidin levels were measured in the experimental group than in the control group [( 11.70±5.64 ) vs. ( 17.82±3.63 ) μg/L; P<0.05 ]. There were 54 patients with mild CHB ( 68.35% ) and 25 cases with moderate-to-severe CHB ( 31.65% ), and lower hepcidin levels were detected in patients with moderate-to-severe CHB than in those with mild CHB [ ( 6.92±2.21 ) vs. ( 13.95±5.36 ) μg/L; P<0.05 ]. The area under the ROC curve, optimal cut-off, sensitivity and specificity of serum hepcidin were 0.903 ( P<0.05 ), 10.365 μg/L, 100.0% and 72.2% for assessment of moderate-to-severe CHB, respectively. Conclusion Serum hepcidin is feasible to evaluate the liver inflammatory activity among patients with CHB.
胡银飞, 何韬, 费云霞, 张祥波, 王洁, 龚玲, 潘孝本, 陈公英. 血清铁调素评估慢性乙肝患者肝组织炎症活动度研究[J]. 预防医学, 2022, 34(3): 240-243,247.
HU Yinfei, HE Tao, FEI Yunxia, ZHANG Xiangbo, WANG Jie, GONG Ling, PAN Xiaoben, CHEN Gongying. Significance of serum hepcidin in assessment of liver inflammation activity among patients with chronic hepatitis B. Preventive Medicine, 2022, 34(3): 240-243,247.
[1] WANG J,DONG A L,LIU G,et al.Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assay[J/OL].Sci Rep,2016,6(2016-10-03)[2022-01-09].https://www.nature.com/articles/srep34252.DOI:10.1038/srep34252. [2] VELA D.Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker[J/OL].Mol Med,2018,24(1)(2018-03-15)[2022-01-09].https://molmed.biomedcentral.com/articles/10.1186/s10020-018-0008-7.DOI:10.1186/s10020-018-0008-7. [3] CANTERO I,ELORZ M,ABETE I,et al.Ultrasound/Elastography techniques,lipidomic and blood markers compared to Magnetic Resonance Imaging in non-alcoholic fatty liver disease adults[J].Int J Med Sci,2019,16(1):75-83. [4] JUNG J Y,SHIM J J,PARK S K,et al.Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population[J].Hepatol Int,2018,13(2):222-233. [5] MEHTA K J,FARNAUD S J,SHARP P A.Iron and liver fibrosis:mechanistic and clinical aspects[J].World J Gastroenterol,2019,25(5):521-538. [6] CAM H,YILMAZ N.Serum hepcidin levels are related to serum markers for iron metabolism and fibrosis stage in patients with chronic hepatitis B:a cross-sectional study[J].Arab J Gastroenterol,2020,21(2):85-90. [7] RADICHEVA M P,ANDONOVA A N,MILCHEVA H T,et al.Serum markers of iron metabolism in chronic liver diseases[J].Open Access Maced J Med Sci,2018,6(6):1010-1016. [8] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].国际流行病学传染病学杂志,2019,46(6):423-446. Chinese Society of Infectious Diseases, Chinese Medical Association,Chinese Society of Hepatology,Chinese Medical Association.Guidelines for prevention and treatment of chronic hepatitis B(2019 version)[J].Int J Epidemiol Infect Dis,2019,46(6):423-446. [9] 张泰和,周晓军,张丽华,等.肝脏诊断病理学[M].南京:江苏科学技术出版社,2006. [10] LICATA A,NEBBIA M E,CABIBBO G,et al.Hyperferritinemia is a risk factor for steatosis in chronic liver disease[J].World J Gastroenterol,2009,15(17):2132-2138. [11] MAO W L,HU Y,LOU Y F,et al.Abnormal serum iron markers in chronic hepatitis B virus infection may be because of liver injury[J].Eur J Gastroenterol Hepatol,2015,27(2):130-136. [12] NAGASHIMA M,KUDO M,CHUNG H,et al.Regulatory failure of serum prohepcidin levels in patients with hepatitis C[J].Hepatol Res,2006,36(4):288-293. [13] GIRELLI D,PASINO M,GOODNOUGH J B,et al.Reduced serum hepcidin levels in patients with chronic hepatitis C[J].J Hepatol,2009,51(5):845-852. [14] TACKE F,NURALDEEN R,KOCH A,et al.Iron parameters determine the prognosis of critically ill patients[J].Crit Care Med,2016,44(6):1049-1058. [15] SPIVAK I,ARORA J,MEINZER C,et al.Low serum hepcidin is associated with reduced short term survival in adults with acute liver failure[J].Hepatology,2019,69(5):2136-2149. [16] 王傲然,李晓玲,门秋爽,等.血清铁蛋白与肝脏疾病研究进展[J].中国肝脏病杂志(电子版),2020,12(4):34-37. WANG A R,LI X L,MEN Q S,et al.Serum ferritin and liver disease[J].Chin J Liver Dis(Electron Version),2020,12(4):34-37. [17] 邓敏,吴云辉,丁韧烨,等.乙型肝炎病毒携带者外周血PD-1、PD-L1、M30、M65与肝脏炎症的相关性研究[J].预防医学,2020,32(12):1242-1245. DENG M,WU Y H,DING R Y,et al.The relationship between the expression of PD-1,PD-L1,M30,M65 in peripheral blood and liver inflammation in hepatitis B virus carriers[J].Prev Med,2020,32(12):1242-1245.
